GNPX - Genprex completes manufacturing scale-up of lung cancer therapy

The clinical-stage micro-cap, Genprex (GNPX), is up +13.6% after the company announced the completion of manufacturing scale-up for its lead product candidate, REQORSA™ immunogene therapy targeting non-small cell lung cancer.Subject to passing final testing currently underway, the scaled-up clinical production will fulfill the supply for the upcoming Phase 1/2 clinical trials combining REQORSA with Tagrisso® of AstraZeneca (Acclaim-1) and Keytruda® of Merck (Acclaim-2). Describing the scaled-up production of clinical-grade REQORSA as a ‘significant manufacturing milestone’, Genprex CEO said the achievement has positioned the company ‘with the manufacturing capability for potential future commercialization in the rapidly growing lung cancer therapeutics market, which is projected to grow to $26.3 billion by 2023.’In January, the company announced that the FDA granted Fast Track Designation for REQORSA for NSCLC in combination therapy with Tagrisso®.

For further details see:

Genprex completes manufacturing scale-up of lung cancer therapy